# Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychological-interventions-schizophrenia-substance-use/ > **Published:** 2026-04-01T14:07:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:49-04:00 > **Clinical Summary:** Explore psychological interventions schizophrenia substance use for dual diagnosis patients. This review highlights effective treatments for co-occurring disorders. --- CED Clinical Relevance  #100High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic SchizophreniaDual DiagnosisSubstance Use DisorderCannabisPsychosocial Interventions Journal JAMA psychiatry Study Type Randomized Trial Population Human participants Why This Matters This [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) addresses a critical treatment gap for patients with dual diagnosis of schizophrenia and substance use disorders, who represent over 40% of schizophrenia patients yet are systematically excluded from most [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Understanding effective psychological interventions for this vulnerable population could significantly improve treatment outcomes and reduce healthcare burden. Clinical Summary This meta-analysis examined randomized controlled trials of psychological and psychosocial interventions for adults with schizophrenia and co-occurring substance use disorders, including cannabis, alcohol, nicotine, and stimulants. The researchers searched comprehensive databases through January 2025 to evaluate efficacy, acceptability, and tolerability of non-pharmacological treatments in this challenging-to-treat population. The study addresses a significant evidence gap, as patients with dual diagnoses are frequently excluded from [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) despite representing nearly half of all schizophrenia patients. Specific intervention outcomes and effect sizes would inform clinical decision-making for this complex patient population. Dr. Caplan’s Take “This research tackles one of psychiatry’s most challenging clinical scenarios where traditional treatment approaches often fall short. The systematic exclusion of dual diagnosis patients from research has left clinicians with limited evidence-based guidance for this substantial patient population.” Clinical Perspective 🧠 Clinicians treating patients with schizophrenia should routinely screen for substance use and recognize that co-occurring disorders are the norm rather than exception. The findings from this meta-analysis could provide evidence-based psychological intervention options beyond medication management alone. Treatment teams should consider integrated approaches that address both conditions simultaneously rather than treating them in isolation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Psychological%20and%20Psychosocial%20Interventions%20for%20People%20With%20Schizophrenia%20and%20C...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41637064/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41637064/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Psychological%20and%20Psychosocial%20Interventions%20for%20People%20With%20Schizophrenia%20and%20C...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41637064/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41637064/](https://pubmed.ncbi.nlm.nih.gov/41637064/) Table of Contents - [FAQ](#FAQ)[How common is substance use disorder among patients with schizophrenia?](#How_common_is_substance_use_disorder_among_patients_with_schizophrenia) - [Are psychological interventions effective for patients with both schizophrenia and substance use disorders?](#Are_psychological_interventions_effective_for_patients_with_both_schizophrenia_and_substance_use_disorders) - [Why are patients with schizophrenia and substance use often excluded from clinical trials?](#Why_are_patients_with_schizophrenia_and_substance_use_often_excluded_from_clinical_trials) - [What types of substances were included in this research on schizophrenia patients?](#What_types_of_substances_were_included_in_this_research_on_schizophrenia_patients) - [What treatment outcomes were measured in this study of dual diagnosis patients?](#What_treatment_outcomes_were_measured_in_this_study_of_dual_diagnosis_patients) - [Related](#Related) ## FAQ #### How common is substance use disorder among patients with schizophrenia? Substance use disorder occurs in approximately 41.7% of individuals with schizophrenia, representing a significantly high co-occurrence rate. This dual diagnosis creates particularly complex treatment challenges and imposes substantial economic burden on healthcare systems. #### Are psychological interventions effective for patients with both schizophrenia and substance use disorders? This [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) and meta-analysis examined the efficacy of psychological and psychosocial interventions specifically for this dual diagnosis population. The study evaluated randomized [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to determine treatment effectiveness, acceptability, and tolerability for patients with co-occurring schizophrenia and substance use disorders. #### Why are patients with schizophrenia and substance use often excluded from clinical trials? Patients with dual diagnosis of schizophrenia and substance use disorders are frequently excluded from clinical trials and systematic reviews due to their complex presentation and treatment challenges. This exclusion creates a significant gap in evidence-based treatment options for this vulnerable population. #### What types of substances were included in this research on schizophrenia patients? The study included patients with schizophrenia who had concurrent use of various substances including alcohol, cannabis, nicotine, and stimulants. No restrictions were applied regarding the specific type of substance used, providing comprehensive coverage of substance use patterns in this population. #### What treatment outcomes were measured in this study of dual diagnosis patients? The research evaluated three key treatment outcomes: efficacy (how well interventions work), acceptability (patient willingness to engage), and tolerability (ability to complete treatment). These measures provide clinicians with comprehensive information about both clinical effectiveness and practical implementation of psychological interventions. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41637064/”, “about”: “jama psychiatry randomized trial psychological psychosocial”, “isPartOf”: “JAMA psychiatry”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.](https://cedclinic.com/schizophrenia-dual-diagnosis-treatment-2025/) A comprehensive meta-analysis examining psychological treatments for schizophrenia patients with substance use disorders. [Read the full study](https://cedclinic.com/schizophrenia-dual-diagnosis-treatment-2025/) [Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia](https://cedclinic.com/tdcs-cannabis-use-disorder-schizophrenia-treatment-trial/) Explore novel treatment approaches using tDCS for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in schizophrenia patients. [Learn about tDCS therapy](https://cedclinic.com/tdcs-cannabis-use-disorder-schizophrenia-treatment-trial/) [Should cannabis be used for mental illnesses? – indica News](https://cedclinic.com/cannabinoid-efficacy-for-mental-health/) An analysis of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in mental health treatment, including risks and benefits for psychiatric conditions. [Explore cannabis and mental health](https://cedclinic.com/cannabinoid-efficacy-for-mental-health/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).